Sanofi Positioning Aflibercept To Compete With Genentech’s Avastin In Certain Settings
This article was originally published in The Pink Sheet Daily
Executive Summary
Company plans to file VEGF Trap for its first indication, ovarian cancer, in 2008, followed by second-line lung cancer and second-line colorectal cancer.